Article Text

Download PDFPDF
Life-saving implantable cardioverter defibrillator therapy in cardiac AL amyloidosis
  1. Ketna S Patel,
  2. Philip N Hawkins,
  3. Carol J Whelan,
  4. Julian D Gillmore
  1. National Amyloidosis Centre, London, UK
  1. Correspondence to Dr Ketna S Patel, ketna.patel{at}


Cardiac involvement is the main determinant of prognosis in systemic monoclonal immunoglobulin light chain (AL) amyloidosis. Ventricular arrhythmias and sudden cardiac death are not uncommon. The electrical events that precede sudden death, and their potential to be treated effectively, remain undefined. There are no European guidelines for the use of implantable cardioverter defibrillator (ICD) in amyloidosis. ICDs in general are not usually offered to patients with a life expectancy of less than 1 year. We describe a patient who presented with cardiac AL amyloidosis who underwent prophylactic ICD implantation for the prevention of sudden cardiac death during treatment with chemotherapy, in whom life-threatening ventricular arrhythmia was successfully terminated over a 3-year period.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.